DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?

Quest Diagnostics (DGX) is set to report Q2 2025 results on July 22, with consensus estimates projecting revenues of $2.72 billion (+13.4% YoY) and EPS of $2.57 (+9.4% YoY). This anticipated growth is driven by robust demand in its Advanced Diagnostics portfolio, expanded health plan access, strategic acquisitions from the past year, and operational efficiencies stemming from automation and AI initiatives. With a history of consistently beating earnings estimates and a positive Zacks Earnings ESP, DGX is positioned for a high probability of another earnings beat.

Analysis

Quest Diagnostics (DGX) is positioned for a strong second-quarter 2025 earnings report, with consensus estimates forecasting significant year-over-year growth in both revenue to $2.72 billion (+13.4%) and EPS to $2.57 (+9.4%). This outlook is supported by multifaceted growth drivers within its core Diagnostics Information Services business, led by the Advanced Diagnostics portfolio, which includes high-demand areas such as cardiometabolic, autoimmune, and women's health testing. Key product rollouts, including the HPV self-collection solution and the commercial launch of the Haystack minimal residual disease (MRD) test, are expected to contribute positively. Furthermore, recent strategic acquisitions are projected to account for a substantial 5.8% of the division's revenue growth. Top-line expansion is also being fueled by expanded health plan access with major providers like Elevance Health and Optum Health. Operationally, the company's "Invigorate" program, targeting 3% annual cost savings through automation and AI, is anticipated to support a 13.6% increase in non-GAAP operating income. Combined with a consistent history of beating earnings estimates and a positive Zacks Earnings ESP of +0.67%, the data points to a high probability of another earnings beat.

Key Decisions for Investors

• Given the strong consensus growth estimates, a consistent history of earnings beats, and a positive Earnings ESP of +0.67%, investors could consider a bullish stance heading into the July 22 report.
• Beyond headline numbers, investors should scrutinize the performance of the Advanced Diagnostics portfolio and the specific revenue contribution from recent acquisitions, projected at 5.8%, to validate the long-term growth narrative.
• It is critical to monitor management's commentary on operating margins and the progress of the 'Invigorate' cost-savings program, as the ability to convert top-line growth into sustained profitability will dictate the stock's post-earnings trajectory.
• Any revision to full-year guidance will be a primary catalyst, as an upgraded outlook based on synergies from new health plan contracts and acquisitions would signal continued momentum.